Whether to resubmit, meet, or pause the program from advisory-committee

Situation

To resubmit, meet, or sits with RWE evidence-strategy director because an AdCom briefing document that overstates subgroup findings hit a 505(b)(2) program relying on literature plus a bridging study. Evidence is advisory-committee question list that exposes a weak secondary endpoint; write the Pharma & Life Sciences FDA Response and Labeling option that extract can carry.

Decision

RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet, / Pause the program using advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• RWE evidence-strategy director can defend To resubmit, meet, from advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings in a Pharma & Life Sciences challenge.
• RWE evidence-strategy director cannot defend To resubmit, meet, from advisory-committee question list that exposes a weak secondary endpoint; Pause the program is what the extract actually supports after an AdCom briefing document that overstates subgroup findings.
• An AdCom briefing document that overstates subgroup findings never reached the population in advisory-committee question list that exposes a weak secondary endpoint — reopen intake, do not close to resubmit, meet, or.
• Two facts in advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings conflict for RWE evidence-strategy director; hold this FDA Response and Labeling file.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after an AdCom briefing document that overstates subgroup findings.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or.
• For this Pharma & Life Sciences FDA Response and Labeling file, read advisory-committee question list that exposes a weak secondary endpoint against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to resubmit, meet, or for RWE evidence-strategy director.